MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally.
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has MaxCyte's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MXCT's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MXCT exceeded the UK Biotechs industry which returned 10.8% over the past year.
Return vs Market: MXCT exceeded the UK Market which returned -16.2% over the past year.
Price Volatility Vs. Market
How volatile is MaxCyte's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs MaxCyte, Inc.'s (LON:MXCT) CEO Overpaid Relative To Its Peers?
2 months ago | Simply Wall StAnalysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 12%
2 months ago | Simply Wall StEarnings Update: MaxCyte, Inc. (LON:MXCT) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Is MaxCyte undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MXCT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MXCT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MXCT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MXCT is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MXCT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MXCT is overvalued based on its PB Ratio (10.5x) compared to the GB Biotechs industry average (3.5x).
How is MaxCyte forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MXCT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).
Earnings vs Market: MXCT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MXCT's is expected to become profitable in the next 3 years.
Revenue vs Market: MXCT's revenue (13.6% per year) is forecast to grow faster than the UK market (3.2% per year).
High Growth Revenue: MXCT's revenue (13.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MXCT's Return on Equity is forecast to be high in 3 years time
How has MaxCyte performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MXCT is currently unprofitable.
Growing Profit Margin: MXCT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MXCT is unprofitable, and losses have increased over the past 5 years at a rate of -31.3% per year.
Accelerating Growth: Unable to compare MXCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MXCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).
Return on Equity
High ROE: MXCT has a negative Return on Equity (-94.8%), as it is currently unprofitable.
How is MaxCyte's financial position?
Financial Position Analysis
Short Term Liabilities: MXCT's short term assets ($24.5M) exceed its short term liabilities ($9.3M).
Long Term Liabilities: MXCT's short term assets ($24.5M) exceed its long term liabilities ($7.0M).
Debt to Equity History and Analysis
Debt Level: MXCT's debt to equity ratio (36%) is considered satisfactory.
Reducing Debt: MXCT had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MXCT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MXCT has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 42.5% each year.
What is MaxCyte current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MXCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MXCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MXCT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MXCT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MXCT's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Doug Doerfler (64yo)
Mr. Douglas Arthur Doerfler, also known as Doug, Co-founded MaxCyte, Inc. in June 1999 and has been its Chief Executive Officer and President since June 1999. Mr. Doerfler served senior corporate developme ...
CEO Compensation Analysis
Compensation vs Market: Doug's total compensation ($USD705.25K) is about average for companies of similar size in the UK market ($USD684.29K).
Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.
|CFO, Company Secretary & Director||4.25yrs||US$445.93k||0.20% $300.5k|
|Executive VP & General Counsel||2.83yrs||no data||no data|
|Executive Vice President of Global Sales||6.5yrs||no data||no data|
|Vice President of Marketing||4.5yrs||no data||no data|
|Executive Vice President of Global Commercial Operations||2.92yrs||no data||no data|
|Chief Medical Officer||2.25yrs||no data||no data|
|Executive Vice President of Business Development for CARMA Cellular Therapies||0.58yr||no data||no data|
Experienced Management: MXCT's management team is considered experienced (3.7 years average tenure).
|CFO, Company Secretary & Director||4.25yrs||US$445.93k||0.20% $300.5k|
|Independent Non-Executive Director||no data||US$51.00k||0.066% $100.6k|
|Independent Non-Executive Director||14.17yrs||US$45.50k||0.49% $749.0k|
|Independent Non-Executive Chairman||no data||US$68.00k||0.14% $221.8k|
|Independent Non-Executive Director||2.42yrs||US$35.00k||no data|
|Independent Non-Executive Director||15.25yrs||US$40.00k||0.32% $495.5k|
|Independent Non-Executive Director||no data||US$40.50k||0.16% $241.2k|
Experienced Board: MXCT's board of directors are seasoned and experienced ( 14.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.6%.
MaxCyte, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: MaxCyte, Inc.
- Ticker: MXCT
- Exchange: AIM
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£153.170m
- Shares outstanding: 76.59m
- Website: https://www.maxcyte.com
Number of Employees
- MaxCyte, Inc.
- 22 Firstfield Road
- Suite 110
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MXCT||AIM (London Stock Exchange AIM Market)||Yes||Common Stock||GB||GBP||Mar 2016|
|MAXC||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||Mar 2016|
|MXCL||AIM (London Stock Exchange AIM Market)||ORD USD0.01 (DI) REG S||GB||GBP||May 2020|
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/02 21:06|
|End of Day Share Price||2020/07/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.